Skip to content

Retrospective Clinical Observation of Bacterial Lysate in the Treatment of Patients with Chronic Bronchitis Complicated with Pulmonary Nodules

Retrospective Clinical Observation of Bacterial Lysate in the Treatment of Patients with Chronic Bronchitis Complicated with Pulmonary Nodules

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064396
Enrollment
Unknown
Registered
2022-10-06
Start date
2022-10-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung nodules

Interventions

1:None

Sponsors

Fudan University Zhongshan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients must meet all of the following criteria: 1. The subject visited our hospital from January 2022 to July 2022 and was diagnosed as "pulmonary nodule" by chest CT; 2. During the treatment, the subjects were followed up periodically as recommended by the doctor, and appropriate follow-up data were available (previous chest CT image records were available, the image quality was in line with the requirements of AI diagnostic system, and there were no obvious respiratory movement artifacts); 3. The subject signs the written informed consent, or refuses to come to the hospital to sign the written informed consent but verbally agrees by telephone, or the subject cannot be contacted after three times; 4. Subjects are between 18 and 90 years old; 5. Subjects received standard oral panfosul therapy or did not receive oral panfosul therapy but received another clinical regimen prescribed by a physician during the aforementioned visit.

Exclusion criteria

Exclusion criteria: 1. Comorbidities: The presence of clinically significant abnormal laboratory values or conditions (e.g., cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, mental, physical impairment, or lung transplantation) at the time of screening that may interfere with treatment or evaluation and affect the results of the study; 2. Patients who are allergic to bacteriolysis products; 3. Patients with autoimmune diseases; 4. Patients who have received immunosuppressive or immunomodulatory therapy (e.g., thymosin, interferon, pidotimod, etc.) within 3 months; 5. Other circumstances that the researcher considers inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
risk probability;

Secondary

MeasureTime frame
Changes in the diameter of pulmonary nodules;Changes in lung nodule volume;Changes in the density of pulmonary nodules;

Countries

China

Contacts

Public ContactYang Dawei

Fudan University Zhongshan Hospital

yang.dawei@zs-hospital.sh.cn+86 13564703813

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026